Smits Evelien L J M, Berneman Zwi N, Van Tendeloo Viggo F I
Vaccine & Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
Oncologist. 2009 Mar;14(3):240-52. doi: 10.1634/theoncologist.2008-0165. Epub 2009 Mar 16.
Following standard therapy that consists of chemotherapy with or without stem cell transplantation, both relapsed and refractory disease shorten the survival of acute myeloid leukemia (AML) patients. Therefore, additional treatment options are urgently needed, especially to fight residual AML cells. The identification of leukemia-associated antigens and the observation that administration of allogeneic T cells can mediate a graft-versus-leukemia effect paved the way to the development of active and passive immunotherapy strategies, respectively. The aim of these strategies is the eradication of AML cells by the immune system. In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.
在包括有或没有干细胞移植的化疗的标准治疗之后，复发和难治性疾病都会缩短急性髓系白血病（AML）患者的生存期。因此，迫切需要额外的治疗选择，尤其是用于对抗残留的AML细胞。白血病相关抗原的鉴定以及同种异体T细胞给药可介导移植物抗白血病效应的观察结果，分别为主动和被动免疫治疗策略的发展铺平了道路。这些策略的目的是通过免疫系统根除AML细胞。在本综述中，概述了正在研究或用于治疗AML的主动和被动免疫治疗策略。对于每种策略，都对当前的技术水平进行了批判性审视，并讨论了未来的前景。
